Are Recommendations That Favor Other Agents Over Angiotensin-Converting Enzyme Inhibitors in Africans With Hypertension Justified?

Peter, Jonathan G; Ntusi, Ntobeko A B; Ntsekhe, Mpiko

Peter, Jonathan G; Ntusi, Ntobeko A B; Ntsekhe, Mpiko.

Affiliation

Peter JG; Division of Allergy and Clinical Immunology, Department of Medicine, University of Cape Town, South Africa (J.G.P.).
Ntusi NAB; Allergy and Immunology Unit, University of Cape Town Lung Institute, South Africa (J.G.P.).
Ntsekhe M; Division of Cardiology, Department of Medicine, University of Cape Town, South Africa (N.A.B.N., M.N.).

Circulation ; 149(11): 804-806, 2024 03 12.

Article in En | MEDLINE | ID: mdl-38466787

Subject(s)

Angiotensin-Converting Enzyme Inhibitors; Hypertension; Humans; Angiotensin-Converting Enzyme Inhibitors/therapeutic use; Hypertension/drug therapy; Hypertension/epidemiology; Risk Factors

Key words

ACE-I; angioedema; angiotensin-converting enzyme inhibitor; hypertension

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Angiotensin-Converting Enzyme Inhibitors / Hypertension Limits: Humans Language: En Journal: Circulation Year: 2024 Type: Article

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google